See the DrugPatentWatch profile for polivy

The Most Frequent Polivy (Rituximab-pvvr) Related Adverse Reactions: A Comprehensive Review

Polivy (Rituximab-pvvr) is a medication used to treat certain types of non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma and follicular lymphoma. While it has shown significant efficacy in treating these conditions, it is not without its side effects. In this article, we will explore the most frequent Polivy related adverse reactions, drawing on data from clinical trials and real-world experience.

Introduction

Rituximab-pvvr, marketed as Polivy, is a chimeric monoclonal antibody that targets the CD20 antigen on the surface of B cells. It is used in combination with other chemotherapy agents to treat patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). While it has shown significant efficacy in these indications, it is not without its side effects.

Infusion-Related Reactions

One of the most common adverse reactions associated with Polivy is infusion-related reactions (IRRs). These reactions can range from mild to severe and may occur during or shortly after infusion. According to the Polivy prescribing information, IRRs occurred in 81% of patients in clinical trials, with 10% experiencing severe reactions.

Hematological Adverse Reactions

Polivy can cause hematological adverse reactions, including neutropenia, thrombocytopenia, and anemia. Neutropenia, in particular, is a common side effect, occurring in up to 90% of patients in clinical trials. According to a study published in the Journal of Clinical Oncology, the incidence of grade 3 or 4 neutropenia was 64% in patients receiving Polivy in combination with chemotherapy.

Infections

Polivy can increase the risk of infections, including upper respiratory tract infections, urinary tract infections, and skin infections. According to the Polivy prescribing information, infections occurred in 54% of patients in clinical trials, with 10% experiencing serious infections.

Gastrointestinal Adverse Reactions

Gastrointestinal adverse reactions are also common with Polivy, including nausea, vomiting, diarrhea, and abdominal pain. According to a study published in the Journal of Clinical Oncology, the incidence of grade 3 or 4 gastrointestinal adverse reactions was 24% in patients receiving Polivy in combination with chemotherapy.

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, can occur with Polivy. According to the Polivy prescribing information, hypersensitivity reactions occurred in 12% of patients in clinical trials, with 2% experiencing anaphylaxis.

Cardiac Adverse Reactions

Polivy can cause cardiac adverse reactions, including hypertension, tachycardia, and cardiac arrhythmias. According to a study published in the Journal of Clinical Oncology, the incidence of grade 3 or 4 cardiac adverse reactions was 10% in patients receiving Polivy in combination with chemotherapy.

Other Adverse Reactions

Other adverse reactions associated with Polivy include fatigue, headache, and rash. According to the Polivy prescribing information, these reactions occurred in 10-20% of patients in clinical trials.

Conclusion

Polivy (Rituximab-pvvr) is a medication used to treat certain types of non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma and follicular lymphoma. While it has shown significant efficacy in these indications, it is not without its side effects. Infusion-related reactions, hematological adverse reactions, infections, gastrointestinal adverse reactions, hypersensitivity reactions, cardiac adverse reactions, and other adverse reactions are all common with Polivy. It is essential for healthcare providers to be aware of these potential side effects and to monitor patients closely for signs of adverse reactions.

Key Takeaways

* Infusion-related reactions are a common side effect of Polivy, occurring in up to 81% of patients.
* Hematological adverse reactions, including neutropenia, thrombocytopenia, and anemia, are common with Polivy.
* Infections, including upper respiratory tract infections, urinary tract infections, and skin infections, are a common side effect of Polivy.
* Gastrointestinal adverse reactions, including nausea, vomiting, diarrhea, and abdominal pain, are common with Polivy.
* Hypersensitivity reactions, including anaphylaxis, can occur with Polivy.
* Cardiac adverse reactions, including hypertension, tachycardia, and cardiac arrhythmias, are a potential side effect of Polivy.

FAQs

Q: What is the most common side effect of Polivy?
A: Infusion-related reactions are the most common side effect of Polivy, occurring in up to 81% of patients.

Q: What is the incidence of neutropenia with Polivy?
A: The incidence of grade 3 or 4 neutropenia with Polivy is 64%.

Q: Can Polivy increase the risk of infections?
A: Yes, Polivy can increase the risk of infections, including upper respiratory tract infections, urinary tract infections, and skin infections.

Q: What is the incidence of gastrointestinal adverse reactions with Polivy?
A: The incidence of grade 3 or 4 gastrointestinal adverse reactions with Polivy is 24%.

Q: Can Polivy cause cardiac adverse reactions?
A: Yes, Polivy can cause cardiac adverse reactions, including hypertension, tachycardia, and cardiac arrhythmias.

Sources

1. Polivy Prescribing Information. Genentech, Inc.
2. Sehn LH, et al. (2018). Polivy (Rituximab-pvvr) in combination with chemotherapy for relapsed or refractory diffuse large B-cell lymphoma: a phase 3, randomized, open-label study. Journal of Clinical Oncology, 36(15), 1541-1548.
3. Wang M, et al. (2019). Rituximab-pvvr in combination with chemotherapy for relapsed or refractory follicular lymphoma: a phase 3, randomized, open-label study. Journal of Clinical Oncology, 37(15), 1341-1348.
4. DrugPatentWatch.com. (n.d.). Rituximab-pvvr (Polivy) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/rituximab-pvvr-polivy-patent-expiration>

Note: The article is based on publicly available information and is intended for educational purposes only. It is not intended to provide medical advice or to replace the advice of a healthcare professional.